XML 80 R61.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Investment in Rafael Pharmaceuticals, Inc. (Details Textual) - USD ($) $ in Thousands |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | ---
Mar. 02, 2017 | Sep. 30, 2016 | Aug. 31, 2016 | Jul. 31, 2017 | Jul. 31, 2016 | Sep. 19, 2017 | Sep. 14, 2017
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Proceeds from issuance of member interests |  |  |  | $ 10,000 | $ 8,800 |  |
Investments |  |  |  | 10,000 |  |  |
Series C convertible notes |  |  |  | 26,894 | 14,024 |  |
Purchase price |  |  |  | 10,000 |  |  |
Additional paid-in capital |  |  |  | 394,462 | 396,243 |  |
Noncontrolling Interest [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Purchase price |  |  |  | 7,250 |  |  |
Howard S. Jonas [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Percentage of direct and indirect interest | 10.00% |  |  |  |  |  |
Purchase price | $ 1,000 |  |  |  |  |  |
Howard S. Jonas [Member] | Additional Paid-in Capital [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Purchase of stock of subsidiary | (200) |  |  |  |  |  |
Howard S. Jonas [Member] | Noncontrolling Interest [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Purchase of stock of subsidiary | $ 1,200 |  |  |  |  |  |
Howard S. Jonas [Member] | IDT Corporation [Member] | Subsequent Event [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Percentage of contractual right to receive additional shares |  |  |  |  |  | 9.00% |
Rafael Pharmaceuticals, Inc. [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Convertible promissory note, principal amount |  |  |  |  | $ 2,000 |  |
Convertible promissory note, rate of interest |  |  |  |  | 3.50% |  |
Maximum amount of investment |  |  |  | 10,000 |  |  |
Maximum exposure to loss |  |  |  | $ 12,100 |  |  |
Proceeds from third party member interests, description |  |  |  | At July 31, 2016, the $8.8 million received was included in "Other current liabilities" in the accompanying consolidated balance sheet pending the issuance of the member interests. |  |  |
Rafael Pharmaceuticals, Inc. [Member] | Convertible promissory note [Member] | Howard and Deborah Jonas [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Series C convertible notes |  |  |  | $ 525 |  |  |
Rafael Pharmaceuticals, Inc. [Member] | Convertible promissory note [Member] | The Howard S. and Deborah Jonas Foundation [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Series C convertible notes |  |  |  | 525 |  |  |
CS Pharma Holdings, LLC [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Maximum amount of investment |  |  |  | 10,000 |  |  |
Noncontrolling interests |  |  |  | $ 7,200 |  |  |
Holds percentages of interest |  |  |  | 50.00% |  |  |
Additional paid-in capital |  |  |  | $ 2,800 |  |  |
CS Pharma Holdings, LLC [Member] | Convertible promissory note ("Series D Note") [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Convertible promissory note, principal amount |  | $ 10,000 |  |  |  |  |
Convertible promissory note, rate of interest |  | 3.50% |  |  |  |  |
Convertible promissory note, maturity date |  | Sep. 16, 2018 |  |  |  |  |
Additional amount of investment funded |  | $ 8,000 | $ 8,000 |  |  |  |
Purchase shares of capital stock percentage |  |  |  | 56.00% |  |  |
Exercise warrants value |  |  |  | $ 10,000 |  |  |
Initial amount of investment amounts paid |  |  |  | $ 5,000 |  |  |
Convertible notes conversion features, description |  |  |  | The Series D Note also includes a mandatory conversion into Rafael common stock upon a qualified initial public offering, and conversion at the holder's option upon an unqualified financing event. In all cases, the Series D Note conversion price is based on the applicable financing purchase price. |  |  |
Warrants expiry date |  |  |  | Dec. 31, 2020 |  |  |
Warrant, description |  |  |  | The exercise price of the warrant is the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments. The minimum initial and subsequent exercises of the warrant shall be for such number of shares that will result in at least $5 million of gross proceeds to Rafael, or such lesser amount as represents 5% of the outstanding capital stock of Rafael, or such lesser amount as may then remain unexercised. The warrant will expire upon the earlier of December 31, 2020 or a qualified initial public offering or liquidation event. |  |  |
IDT-Rafael Holdings, LLC [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Contractual right to receive additional shares, description |  |  |  | (i) Food and Drug Administration approval of a Rafael drug application, (ii) an initial public offering of Rafael at a valuation of over $500 million, or (iii) a sale of Rafael above certain valuations. Currently, none of the conditions have been satisfied and the right remains contingent. On September 14, 2017, IDT-Rafael Holdings distributed this right to its members on a pro rata basis such that the Company received the right to 9% of the outstanding capital stock of Rafael and Mr. Jonas received the right to 1% of the outstanding capital stock of Rafael. In addition, as compensation for assuming the role of Chairman of the Board of Rafael, and to create additional incentive to contribute to the success of Rafael, on September 19, 2017, the Company transferred its right to receive 9% of the outstanding capital stock of Rafael to Mr. Jonas. The right is further transferable at the discretion of Mr. Jonas. |  |  |
IDT-Rafael Holdings, LLC [Member] | Subsequent Event [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Percentage of contractual right to receive additional shares |  |  |  |  |  |  | 10.00%
IDT-Rafael Holdings, LLC [Member] | IDT Corporation [Member] | Subsequent Event [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Percentage of contractual right to receive additional shares |  |  |  |  |  |  | 9.00%
IDT-Rafael Holdings, LLC [Member] | Howard S. Jonas [Member] | Subsequent Event [Member] |  |  |  |  |  |  |
Investment in Rafael Pharmaceuticals, Inc. (Textual) |  |  |  |  |  |  |
Percentage of contractual right to receive additional shares |  |  |  |  |  |  | 1.00%

X
- Definition Description of contractual right to receive additional shares. + References No definition available. + Details
Name: | idt_ContractualRightToReceiveAdditionalSharesDescription
Namespace Prefix: | idt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of contractual right to receive additional shares. + References No definition available. + Details
Name: | idt_ContractualRightToReceiveAdditionalSharesPercentage
Namespace Prefix: | idt_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Exercise warrants value. + References No definition available. + Details
Name: | idt_ExerciseWarrantsValue
Namespace Prefix: | idt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial amount of investment amounts paid. + References No definition available. + Details
Name: | idt_InitialAmountOfInvestmentAmountsPaid
Namespace Prefix: | idt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | idt_InvestmentInRafaelPharmaceuticalsIncTextualAbstract
Namespace Prefix: | idt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Investment warrants exercise terms and expiration. + References No definition available. + Details
Name: | idt_InvestmentWarrantsExerciseTermsAndExpiration
Namespace Prefix: | idt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum amount to be invested. + References No definition available. + Details
Name: | idt_MaximumAmountToBeInvested
Namespace Prefix: | idt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of direct and indirect interest. + References No definition available. + Details
Name: | idt_PercentageOfDirectAndIndirectInterest
Namespace Prefix: | idt_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Proceeds from issuance of member interests. + References No definition available. + Details
Name: | idt_ProceedsFromIssuanceOfMemberInterests
Namespace Prefix: | idt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description of proceeds from third party member interests. + References No definition available. + Details
Name: | idt_ProceedsFromThirdPartyMemberInterestsDescription
Namespace Prefix: | idt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash received on stock transactions. + References No definition available. + Details
Name: | idt_PurchaseOfStockOfSubsidiary
Namespace Prefix: | idt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchase shares of capital stock. + References No definition available. + Details
Name: | idt_PurchaseSharesOfCapitalStock
Namespace Prefix: | idt_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Remaining amount of investment. + References No definition available. + Details
Name: | idt_RemainingAmountOfInvestment
Namespace Prefix: | idt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expiration date of warrants held. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Article 12 -Section 13 -Sentence Column A + Details
Name: | invest_InvestmentWarrantsExpirationDate
Namespace Prefix: | invest_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_AdditionalPaidInCapital
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644 + Details
Name: | us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399 + Details
Name: | us-gaap_DebtInstrumentInterestRateEffectivePercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_DebtInstrumentMaturityDate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_LongTermInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4568740-111683 + Details
Name: | us-gaap_MinorityInterestPeriodIncreaseDecrease
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of long-term investments classified as other. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.1(f)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherLongTermInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash inflow resulting from the sale of an interest in a corporate unit during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfInterestInCorporateUnit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=77990344&loc=d3e5728-111685 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=77990344&loc=d3e5747-111685 + Details
Name: | us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=idt_JonasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | invest_InvestmentAxis=idt_RafaelPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=idt_ConvertiblePromissoryNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=idt_HowardAndDeborahJonasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=idt_HowardSAndDeborahJonasFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | invest_InvestmentAxis=idt_CsPharmaHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | invest_InvestmentAxis=idt_IdtRafaelHoldingsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |